Equities Analysts Set Expectations for ASND FY2029 Earnings

Ascendis Pharma A/S (NASDAQ:ASND - Free Report) - Wedbush raised their FY2029 earnings estimates for shares of Ascendis Pharma A/S in a report issued on Wednesday, February 12th. Wedbush analyst Y. Zhong now anticipates that the biotechnology company will earn $14.13 per share for the year, up from their prior forecast of $13.76. Wedbush has a "Outperform" rating and a $181.00 price objective on the stock. The consensus estimate for Ascendis Pharma A/S's current full-year earnings is ($7.12) per share.

ASND has been the topic of a number of other research reports. Stifel Nicolaus increased their price objective on shares of Ascendis Pharma A/S from $200.00 to $207.00 and gave the stock a "buy" rating in a report on Friday, November 15th. JPMorgan Chase & Co. raised their target price on shares of Ascendis Pharma A/S from $167.00 to $168.00 and gave the company an "overweight" rating in a research note on Thursday, February 13th. Oppenheimer reduced their target price on shares of Ascendis Pharma A/S from $190.00 to $180.00 and set an "outperform" rating on the stock in a research note on Friday, November 15th. UBS Group began coverage on shares of Ascendis Pharma A/S in a research note on Tuesday, January 7th. They issued a "buy" rating and a $196.00 target price on the stock. Finally, Evercore ISI raised their target price on shares of Ascendis Pharma A/S from $220.00 to $260.00 and gave the company an "outperform" rating in a research note on Tuesday. Two investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $197.36.

Ascendis Pharma A/S Stock Up 9.1 %

NASDAQ:ASND traded up $13.09 during mid-day trading on Friday, reaching $157.17. 924,685 shares of the company were exchanged, compared to its average volume of 508,222. Ascendis Pharma A/S has a 12 month low of $111.09 and a 12 month high of $161.00. The company has a fifty day moving average of $133.20 and a 200 day moving average of $132.57. The stock has a market cap of $9.54 billion, a PE ratio of -19.45 and a beta of 0.64.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last issued its quarterly earnings data on Wednesday, February 12th. The biotechnology company reported ($0.68) EPS for the quarter, topping analysts' consensus estimates of ($1.32) by $0.64.

Institutional Trading of Ascendis Pharma A/S

A number of hedge funds have recently modified their holdings of the company. RA Capital Management L.P. raised its position in shares of Ascendis Pharma A/S by 4.1% in the 4th quarter. RA Capital Management L.P. now owns 10,112,744 shares of the biotechnology company's stock valued at $1,392,221,000 after acquiring an additional 402,316 shares during the period. Westfield Capital Management Co. LP raised its holdings in Ascendis Pharma A/S by 3.4% during the 3rd quarter. Westfield Capital Management Co. LP now owns 5,133,766 shares of the biotechnology company's stock worth $766,523,000 after buying an additional 170,942 shares during the period. Avoro Capital Advisors LLC raised its holdings in Ascendis Pharma A/S by 2.3% during the 4th quarter. Avoro Capital Advisors LLC now owns 5,103,055 shares of the biotechnology company's stock worth $702,538,000 after buying an additional 114,167 shares during the period. Artisan Partners Limited Partnership raised its holdings in Ascendis Pharma A/S by 0.9% during the 4th quarter. Artisan Partners Limited Partnership now owns 4,450,420 shares of the biotechnology company's stock worth $612,689,000 after buying an additional 39,309 shares during the period. Finally, Janus Henderson Group PLC raised its holdings in Ascendis Pharma A/S by 4.6% during the 4th quarter. Janus Henderson Group PLC now owns 4,380,382 shares of the biotechnology company's stock worth $602,910,000 after buying an additional 193,688 shares during the period.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.